top of page
Crossbow-logo-color_2x.png
Crossbow Therapeutics © Copyright 2024

Expanding the reach of antibody therapeutics​

Determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens.

antibody-2.png

Why Crossbow

We aim to cure cancer. Our team is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.​

 ​​

We chose the name Crossbow because our next-generation therapies embody the precision and power of a crossbow. With unparalleled accuracy and potency, our T-Bolt™ molecules strike tumor cells like a crossbow shoots bolts at its target.​​

 ​

Join us on our bold quest to broaden the benefits of immunotherapy and improve the lives of people living with cancer.

What we do

slide1.png

Selecting from the expanding universe of cancer antigens

We identify, validate and prioritize the most promising cancer antigens for our T-Cell Receptor mimetic (TCRm) discovery efforts​.

slide2.png

Creating high-quality TCR-mimetics​

Using a proprietary technology engine, we develop highly potent, highly accurate antibodies, targeting tumor-specific peptides presented by Major Histocompatibility Complex (MHC), thus mimicking T-Cell Receptors (TCRs)​.

slide3.png

Developing innovative products

Crossbow’s TCRm antibodies are incorporated into easy-to-assemble T-Cell engagers and other immunotherapies, optimizing manufacturability and potency, and minimizing tumor resistance​.

Who we are

A team of international, collaborative and experienced inventors, drug developers and company builders. We value scientific excellence, passion, integrity, innovation, transparency, respect and accountability. We embrace problems deemed impossible to solve.

Join us

Working at Crossbow

Our people are the key to everything we accomplish. We offer outstanding programs to support your career and personal life.

Hit your next career target at Crossbow!

  • Senior Scientist/Principal Scientist, Biology: Learn more

News & Media

Keep up to date with everything happening at Crossbow.

March 5, 2024

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

October 11, 2023

Crossbow Therapeutics Announces Formation of its Scientific Advisory Board

July 11, 2023

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

Contact Us

heashots_updated3.png

Briggs Morrison, M.D.

Chief Executive Officer,

President

174857.png
heashots_updated5.png

Dmitri
Wiederschain, Ph.D.

Chief Scientific Officer

174857.png
shaliny_alt_IMG_2664_nobg.png

Shaliny Kushwaha, B.A.

Senior Vice President, Head of Regulatory Affairs and Clinical Development Operations

174857.png
heashots_updated6.png

Geraldine Paulus, Ph.D.

Co-founder, Vice President, Head of Corporate Development and Operations

174857.png
heashots_updated10.png

Michael
Princiotta, Ph.D.

Senior Vice President,

Head of Biology